|
GGPS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.63870094849995E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.40529978951565E-10 |
| Normal-vs-Stage2 |
3.842400E-04 |
| Normal-vs-Stage3 |
1.01770000204837E-08 |
| Normal-vs-Stage4 |
2.46225262401367E-12 |
| Stage1-vs-Stage2 |
2.810600E-01 |
| Stage1-vs-Stage3 |
5.168800E-01 |
| Stage1-vs-Stage4 |
2.616900E-03 |
| Stage2-vs-Stage3 |
1.867840E-01 |
| Stage2-vs-Stage4 |
2.924300E-03 |
| Stage3-vs-Stage4 |
4.666500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.70860001094775E-11 |
| Normal-vs-AfricanAmerican |
5.013200E-04 |
| Normal-vs-Asian |
5.07749999822948E-08 |
| Caucasian-vs-AfricanAmerican |
5.256200E-01 |
| Caucasian-vs-Asian |
8.867400E-01 |
| AfricanAmerican-vs-Asian |
5.808200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.67139999010624E-09 |
| Normal-vs-Female |
2.71459965617282E-10 |
| Male-vs-Female |
5.464800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.11560000021416E-09 |
| Normal-vs-Age(41-60Yrs) |
5.99900018549704E-10 |
| Normal-vs-Age(61-80Yrs) |
1.16079999945562E-07 |
| Normal-vs-Age(81-100Yrs) |
6.523400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.874400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.973600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.062400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.887400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.512200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.027800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.863600E-02 |
| Classical-VS-Follicular |
8.660000E-01 |
| Classical-VS-Other |
3.806200E-01 |
| Classical-VS-Normal |
8.20040000348854E-08 |
| Tall-VS-Follicular |
7.772100E-02 |
| Tall-VS-Other |
9.215400E-01 |
| Tall-VS-Normal |
5.96700000521366E-08 |
| Follicular-VS-Other |
3.828200E-01 |
| Follicular-VS-Normal |
1.75682999999927E-05 |
| Other-VS-Normal |
1.364960E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.66899971410351E-10 |
| Normal-vs-N1 |
1.37099998021029E-09 |
| N0-vs-N1 |
1.420220E-01 |
|
|
